
Berkeley Lights BLI
Quartalsbericht 2023-Q2
hinzugefügt 14.08.2023
Berkeley Lights Betriebsaufwand 2011-2026 | BLI
Betriebsaufwand Jährlich Berkeley Lights
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 152 M | 127 M | 84.9 M | 60 M | 44.3 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 152 M | 44.3 M | 93.7 M |
Betriebsaufwand Vierteljährlich Berkeley Lights
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53.2 M | 36.3 M | - | 36.6 M | 38.5 M | 35.1 M | - | 35.4 M | 30.6 M | 27.6 M | - | 21 M | 19.1 M | 18.2 M | - | 15.9 M | 15.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 53.2 M | 15.2 M | 29.4 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | ||
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | ||
|
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | ||
|
Biogen
BIIB
|
5.39 B | $ 177.27 | 0.62 % | $ 25.8 B | ||
|
ANI Pharmaceuticals
ANIP
|
127 M | $ 81.19 | -0.98 % | $ 1.57 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Amgen
AMGN
|
9.33 B | $ 339.82 | -0.91 % | $ 182 B | ||
|
Aeglea BioTherapeutics
AGLE
|
209 M | - | - | $ 1.01 B | ||
|
BioNTech SE
BNTX
|
512 M | $ 114.47 | -1.97 % | $ 27.2 B | ||
|
Burford Capital Limited
BUR
|
106 M | $ 9.65 | -0.16 % | $ 1.52 B | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
Aytu BioScience
AYTU
|
53.7 M | $ 2.56 | -0.78 % | $ 16.1 M | ||
|
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.23 | -0.92 % | $ 7.77 B | ||
|
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | ||
|
CASI Pharmaceuticals
CASI
|
38.9 M | $ 0.99 | - | $ 135 M | ||
|
Catalyst Biosciences
CBIO
|
176 M | $ 10.0 | -1.43 % | $ 658 M | ||
|
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | ||
|
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | ||
|
Cerus Corporation
CERS
|
135 M | $ 2.3 | -1.08 % | $ 424 M | ||
|
Aptose Biosciences
APTO
|
26.3 M | - | -45.71 % | $ 1.2 M | ||
|
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | ||
|
Cellectis S.A.
CLLS
|
109 M | $ 3.81 | -4.51 % | $ 116 M | ||
|
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | ||
|
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | ||
|
Beam Therapeutics
BEAM
|
479 M | $ 28.26 | -3.52 % | $ 2.33 B | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
Ascendis Pharma A/S
ASND
|
338 M | $ 223.79 | -0.07 % | $ 5 B | ||
|
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | ||
|
Atreca
BCEL
|
98.7 M | - | -11.76 % | $ 5.79 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
731 M | $ 68.89 | -0.33 % | $ 9.21 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
190 M | $ 24.53 | -0.2 % | $ 2.91 B | ||
|
Cardiff Oncology
CRDF
|
49.3 M | $ 1.68 | 3.75 % | $ 80.1 M | ||
|
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | ||
|
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
28.5 M | - | -9.72 % | $ 5.89 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
141 M | - | -15.15 % | $ 60.3 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 4.03 | -1.71 % | $ 8.77 B | ||
|
Amneal Pharmaceuticals
AMRX
|
539 M | $ 13.77 | -2.45 % | $ 4.25 B | ||
|
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | ||
|
Bellerophon Therapeutics
BLPH
|
22.4 M | - | -74.18 % | $ 955 K | ||
|
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B |